BGL Advises in the Sale of Preclinical ADME-Toxicology Services Provider Cyprotex PLC

Brown Gibbons Lang & Company (BGL) is pleased to announce the sale of Cyprotex PLC (AIM:CRX) to Evotec AG (XTRA:EVT). BGL’s Healthcare & Life Sciences team served as the exclusive financial advisor to Cyprotex in the transaction. Evotec acquired 100 percent of the outstanding shares of Cyprotex in an all-cash transaction valued at £55.7 million effective December 15, 2016.

With the acquisition, Evotec will strengthen its high-end drug discovery platform and capabilities with access to the market’s most industrialized ADME-Tox platform and proven expertise in in vitro ADME screening, mechanistic and high-content toxicology screening, and predictive modeling.

About Cyprotex

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1,500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry, and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010, and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics, and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target-based screening. The Company’s core capabilities include high quality in vitro ADME services, mechanistic toxicology, and high content toxicology screening services, including its proprietary CellCiphr(R) toxicity prediction technology, bioscience services, and predictive modeling solutions including Cloe(R) PK, chemPK(TM), chemTarget, chemTox, and DDI-Fusion and a range of skin, ocular, and endocrine disruption services. For more information, please visit www.cyprotex.com.

About Evotec

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Evotec operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target to clinic to meet the industry’s need for innovation and efficiency in drug discovery. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies, as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes, and complications of diabetes, pain and inflammation, oncology, and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical, and discovery stages.   For additional information please go to www.evotec.com.